



Collaborate Meeting Mayo Clinic Trondheim Renal Research Group/ Norwegian Society of Nephrology

Scandic Nidelven, Trondheim, Sept 1st – 2nd 2016

WEDNESDAY August 31st

PRESYMPOSIUM: RENAL RESEARCH GROUP

<i>Chairman Knut Aasarød</i>	<i>Presymposium</i>	
19.00-19.30	FSGS: primary and secondary	Fernando Fervenza, Mayo
<u>Thursday SEPT 1st</u> 09.00-09.30	Lessons learned from the VICTOR trial - CMV treatment, diagnostics and pathogenesis in transplanted patients.	Anders Åsberg, Oslo
09.30-10.00	FSGS and transplantation	Hatem Amer, Mayo

THURSDAY Sept 1st

10.00-10.25	Registration	
10.25	Welcome	Knut Aasarød, Trondheim
<i>Chairman Cecilia Øien</i>	<i>Transplantation I</i>	
10.30 - 11.00	Post transplant diabetes mellitus	Trond Jensen, Oslo
11.00-11.30	Transplantation in the elderly	Kristian Heldal, Skien
11.45-12.00	Coffee Break	
12.00-12.30	Post-transplant proteinuria- implication for management	Hatem Amer, Mayo
12.30-13.00	Incentivization of living donation: is it time to cross the bridge?	Sundaram Hariharan, Pittsburgh
13.00-14.00	Lunch	
<i>Maria Radtke</i>	<i>Clinical nephrology I</i>	
14.00-14.30	ANCA-associated vasculitis: Remission maintenance: are we doing what we think we're doing?	Ulrich Specks, Mayo
14.30 -15.00	C3 glomerulonephritis - Update	Sanjeev Sethi, Mayo

15.00-15.30	"Uric acid – its role as risk factor in the general population"	Marit Solbu, Tromsø
15.45-16.00	Coffee Break	
16.00-16.30	Autosomal Dominant Polycystic Kidney	Vicente Torres, Mayo
<i>Chairman Stein Hallan</i>	<i>Hypertension</i>	
16.30-17.00	Secular trends in the prevalence of chronic kidney disease and the influence of cardiovascular risk factors	Stein Hallan, Trondheim
17.00-17.30	Blood pressure and hypertensive nephropathy – a complex relationship	Bjørn Odvar Eriksen, Tromsø
17.30-17.45	Coffee Break	
17.45-18.15	Renovascular Hypertension and Ischemic Nephropathy: where are we now?	Stephen C Textor, Mayo
18.15-18.45	SPRINTing to new blood pressure targets	Joachim Ix, San Diego
18.45 -19.15	Renal dysfunction complicating treatment of hypertension	Biff Palmer, Dallas, Texas
20.00	Dinner	

FRIDAY SEPT 2nd

<i>Chairman Inger Karin Lægreid</i>	<i>Clinical nephrology II</i>	
07.30-08.00	Membranous nephropathy – an update on treatment	Fernando Fervenza, Mayo
08.00-08.30	End of life preferences and care of patients with chronic kidney disease	Paul Mueller, Mayo
08.30-09.00	Novel role of mitochondria in chronic kidney disease	Kumar Sharma, San Diego
09.00-09.30	Fibrosis: Does epithelial-to-mesenchymal transition play a role?	Hans-Peter Marti, Bergen
09.30-09.45	Coffee Break	
<i>Chairman Egil Hagen</i>	<i>Clinical nephrology III</i>	
09.45-10.15	Key pathogenic factors in nephrolithiasis: Not all stones are created equal	John Lieske, Mayo
10.15-10.45	Fluid responsiveness in AKI	Kianoush Kashani, Mayo
10.45-11.15	Oral anticoagulation in dialysis patients with atrial fibrillation: uncertainties and opportunities	An De Vriese, Brügge, Belgium.
11.15-11.45	Approach to the treatment of hyponatremia	Biff Palmer, Dallas Texas
11.45	Summary and adjourn, Lunch	